Pink Sheets: IGENE Biotechnology Inc. (IGNE) news stock charts
IGENE Biotechnology Inc. (IGNE/IGNE.PK) Penny Investment Summary:
IGENE Biotechnology, Inc. engages in the development, production, and marketing of value-added specialty biochemical products in the United States and internationally. It primarily focuses on the research development of fermentation technology, nutrition, and health products and applications. The company offers AstaXin, a natural source of astaxanthin, which is a pigment that imparts the characteristic red color to the flesh of salmon, trout, prawns, and various other types of fish and shellfish. It also formulated natural astaxanthin as a super-antioxidant for the dietary supplement market. The company, formerly known as IGI Biotechnology, Inc., was founded in 1981 and is based in Columbia,...www.igene.com
18 Employees
Founded in 1981
IGENE BIOTECHNOLOGY INC (IGNE:OTC)
LAST $0.01 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of 8:10 PM 03/16/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of IGENE BIOTECHNOLOGY INC (IGNE)
|
OPEN
$0.01
|
PREVIOUS CLOSE
$0.01
|
|
|
DAY HIGH
$0.01
|
DAY LOW
$0.01
|
|
|
52 WEEK HIGH
08/24/09 - $0.04
|
52 WEEK LOW
10/27/09 - $0.0020
|
|
|
MARKET CAP
15.6M
|
AVERAGE VOLUME 10 D
4.4K
|
|
|
EPS TTM
$-0.01
|
SHARES OUTSTANDING
1.6B
|
|
|
IGNE Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for IGENE BIOTECHNOLOGY INC (IGNE)
IGENE Biotechnology Inc. announced delayed annual 10-K filing
04/1/2009
On 04/01/2009, IGENE Biotechnology Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
IGENE Biotechnology Inc. Auditor Raises 'Going Concern' Doubt
04/1/2009
IGENE Biotechnology Inc. filed its 10-K on April 01, 2009 for the period ending December 31, 2008. In this report its auditor, McElravy, Kinchen & Associates PC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
IGENE Biotechnology Inc. and Archer-Daniels-Midland Co. Forms Joint Venture
01/21/2009
IGENE Biotechnology Inc. announced that it has entered into an agreement with Archer-Daniels-Midland Company pursuant to which the company and ADM formed a joint venture to manufacture and sell astaxanthin and derivative products throughout the world. Each of the company and ADM has a 50% ownership interest in the joint venture and has equal representation on the Board of Managers of the joint venture.
IGENE Biotechnology Inc. financial resources
IGNE Competitors
| Company | Last | Change | |
| No competitor information is available for IGNE. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | IGNE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.3x |
|
|
IGNE |
||
|
IGNE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Pink Sheets: More Recent Financial News About IGENE Biotechnology Inc.
IGENE BIOTECHNOLOGY INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
2009-12-02 02:23:45
Quote: IGENE BIOTECHNOLOGY INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
IGENE BIOTECHNOLOGY INC
1-Dec-2009Amendments to Articles of Inc. or Bylaws; Change in Fiscal YearPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informa...Read article
IGENE BIOTECHNOLOGY INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi
2009-11-30 01:58:53
Quote: Item 1.01 Entry into a Material Definitive Agreement
On January 8, 2009, Igene Biotechnology, Inc. (the "Company") entered into an
agreement with Archer-Daniels-Midland Company ("ADM") pursuant to which the
Company and ADM formed a joint venture (the "Joint Venture") to manufacture and
sell astaxanthin and derivative products throughout the world. Each of the
Company and ADM has a 50% ownership interest in the Joint Venture and has equal
representation on the Board...Read article
Would you like to leave a comment about IGENE Biotechnology Inc. IGNE/IGNE.PK
Find out what social network information about IGENE Biotechnology Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides IGENE Biotechnology Inc.'s Penny Stock there is more great penny stock and market information at Realpennies